What Is FOXO4-DRI? Dosage, Half-Life & How to Track It

What FOXO4-DRI is and how it works

FOXO4-DRI is a synthetic D-retro-inverso peptide — meaning its amino acid sequence and chirality are engineered in reverse, a trick that makes it far more resistant to being broken down by the body’s normal protein-degrading enzymes than a standard peptide of the same sequence. It’s designed to interrupt the interaction between two proteins, FOXO4 and p53, inside senescent cells.

Senescent cells are cells that have stopped dividing but refuse to die, and they accumulate with age, secreting inflammatory signals that damage surrounding tissue. FOXO4 normally protects these cells from self-destructing; blocking the FOXO4–p53 interaction lets p53 do what it would otherwise do — trigger the cell’s own apoptosis (programmed death) — and the mechanism appears selective for senescent cells while sparing healthy ones.

This is genuinely early-stage science. The core findings come from a 2017 mouse study (where the peptide is often referred to by its research name, Proxofim), and there is no completed human clinical trial establishing dosing, efficacy, or safety in people. Anyone discussing a “protocol” for FOXO4-DRI is extrapolating from animal data, not following an established human standard.

Typical dosing & reconstitution

FOXO4-DRI is reconstituted with bacteriostatic water — a 10 mg vial in 3 mL gives roughly 3.33 mg/mL, where one insulin-syringe unit is about 33.3 mcg.

This gradual titration over 16 weeks is a community-derived schedule extrapolated from animal-study dose ranges, not a clinically validated human protocol. The reconstitution calculator handles the concentration math for any vial/water combination.

Half-life & what the evidence actually supports

There’s no published human pharmacokinetic data for FOXO4-DRI. What is known from the underlying chemistry is that the D-retro-inverso design specifically exists to resist protease degradation — the whole point of building it “backwards” is to survive longer in circulation than a normal peptide of the same sequence would.

That’s a mechanistic reason to expect a longer functional window than a typical short peptide, not a measured number. Senolytic strategies in animal research are also often studied as intermittent, “hit-and-run” dosing rather than continuous daily use, on the theory that clearing senescent cells doesn’t require sustained exposure — a meaningfully different model than the daily-dosing schedule community protocols actually use.

What to track & considerations

Safety data in humans is essentially absent. There is no established side-effect profile to reference, no dose-finding study, and no long-term safety data — this is the most speculative compound in this batch, and it should be treated that way.

If you are tracking it regardless, the useful log is simple: dose, date, and site — a plain record you and a physician could review, rather than any specific outcome marker this page would be irresponsible to suggest chasing.

Frequently asked questions